The US Food and Drug Administration-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test.
Safety and Efficacy of Anti–Human Epidermal Growth Factor 2 Agents in the Treatment of Biliary Tract Cancers: A Systematic Review Eligible patients had AKT1 E17K–mutated metastatic tumors that ...
(A) Gene-based burden test of rare coding-altering mutations (max gnomAD AF ≤ 0.01). (B) Mutation burden analysis of rare pathogenic noncoding mutations (max gnomAD AF ≤ 0.001; predicted deleterious ...
Webinar 3 will focus on the computational aspects of comprehensive genomic oncology panels. We'll discuss computational infrastructure options and bioinformatics approaches for extracting a variety of ...
View all available purchase options and get full access to this article. The following represents disclosure information provided by authors of this manuscript. All relationships are considered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results